Capricor Therapeutics vs Keros Therapeutics
CAPR and KROS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CAPR and KROS compare
Capricor Therapeutics is the larger company, worth 2.4 times as much as Keros Therapeutics ($483M against $199M).
Keros Therapeutics scores higher on the StockData Score (7 against 6 for Capricor Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CAPR | KROS |
|---|---|---|
| Size and price | ||
| Market cap | $483M | $199M |
| Share price | $8.30 | $10.03 |
| Change, 1 year | 43.8% | −42.0% |
| Change, 5 years | 143% | −82.1% |
| Beta (5Y) | 0.43 | 2.22 |
| Employees | 231 | 78 |
| StockData Score | ||
| Total score | 6 | 7 (better) |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 13.7× |
| P/B | 2.0× | 0.8× (better) |
| FCF yield | −23.8% (better) | −24.4% |
| Growth | ||
| Revenue growth (TTM) | – | −93.7% |
| Net income growth (TTM) | – | −543% |
| EPS growth (TTM) | – | −1287% |
| Profitability | ||
| Operating margin | – | −698% |
| Net margin | – | −572% |
| FCF margin | – | −334% |
| Return on equity | −73.7% | −17.2% (better) |
| Return on invested capital | – | −755% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 7.35 | 21.96 (better) |
| Altman Z-score | 0.39 | 2.07 (better) |
| Piotroski F-score | 3 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 67.6% | 101% |
| Held by insiders | 1.6% | 53.3% |
| Insider net buying, 12 months | −$8.4M | −$447K (better) |
| Short interest, % of float | 32.8% | 11.7% |
Go deeper
- CAPR stock overview
- CAPR income statement
- CAPR valuation and score
- KROS stock overview
- KROS income statement
- KROS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.